A blood-test formula most readers have never heard of now sits at the front door of fatty liver care, and 2026 is the year the instructions around it got specific. The updated AGA Clinical Care Pathway for MASLD, published in Gastroenterology (2026;171:164-183, PMID 41812830), lays out exactly which number leads where, and every person with metabolic risk factors benefits from knowing the sequence.
The pathway starts with who should be screened at all: adults with type 2 diabetes, people with overweight or obesity plus another metabolic risk factor, and anyone with incidental steatosis on imaging or unexplained aminotransferase elevation. That list covers a large share of the adults reading a site like this one, which is precisely why the numbers matter.
Step one is the FIB-4 index, calculated from four routine values: age, AST, ALT, and platelets. A score below 1.3 is generally managed in primary care with repeat testing every 1 to 2 years. For adults aged 65 and older the low-risk cutoff rises to below 2.0, a deliberate adjustment that cuts false alarms in an older population.
Scores above those thresholds move to step two: vibration-controlled transient elastography, the FibroScan that measures liver stiffness in kilopascals. When elastography is unavailable, the enhanced liver fibrosis blood test is the fallback. The pathway is sequential by design, cheap test first, expensive test only for those who need it.
The 8 kPa line is the pathway’s hinge. Stiffness below 8.0 kPa counts as low risk, while 8.0 kPa or above generally warrants hepatology referral and possible confirmatory testing. That single number converts an abstract risk conversation into a concrete next step, which is what staging systems are for.
Treatment talk now has a defined on-ramp. For patients with metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis, the pathway incorporates the FDA-approved therapies, resmetirom and semaglutide, selected by disease severity, comorbidities, contraindications, patient preference, access, and cost. Sequential rather than simultaneous initiation may be reasonable when combination treatment is considered.
Everything below that line is lifestyle, and the pathway says so without apology: weight loss, physical activity, alcohol avoidance, and treatment of diabetes, obesity, dyslipidemia, and blood pressure. The drugs treat the fibrotic stage; the plate treats the stage most readers are actually in. That plate is built from ordinary rows, too: a change as small as the one between regular crackers and the low-sodium saltine row is exactly the grain of the lifestyle package.
Why did the pathway need an update at all? Because the gap between guideline and practice is enormous. The implementation literature is blunt: fewer than one-third of eligible patients get assessed in ordinary clinical practice, and primary care clinicians report little experience calculating or interpreting FIB-4 despite its four routine inputs.
The 2026 implementation studies measure exactly that gap. A study in the Journal of the American Board of Family Medicine (2026;39(1):167166) put a computerized decision-support prompt in three primary care clinics: it triggered on 1,410 encounters where FIB-4 plus diabetes or metabolic risk factors met criteria, and confirmatory testing orders rose from zero to 2.1 percent. Better than nothing, still a rounding error against the need.
A more ambitious model is running in Madrid. The LiverSeek programme makes the laboratory information system itself calculate FIB-4 automatically whenever a routine blood panel hits high-risk combinations, then reflexively orders the second-tier fibrosis tests from the same tube of blood, with zero added work for the clinician. The program covers roughly 350,000 people across 11 primary care centers.
For the reader doing the math at home, honesty about what FIB-4 is and is not matters. It is a risk sorter built from four numbers, good at telling who needs a closer look. It is not a liver fat measure, it rises with age for reasons unrelated to the liver, and an intermediate score in the gray zone is exactly the situation step two exists to resolve.
The pathway also names the management package that surrounds any staging result: lifestyle intervention as the base layer, cardiovascular risk treated as seriously as the liver itself, bariatric surgery appropriate for selected patients, and decompensated cirrhosis managed by specialists. Staging is triage, not sentencing.
Where does a reader with a high score actually go? The pathway’s answer is the primary care clinician first, because the confirmatory tests need ordering and the results need a clinician who can read them alongside the whole metabolic picture. Self-ordered FibroScans exist, but a stiffness number without context breeds more anxiety than action.
The one-year version of this story: the threshold numbers did not change much from prior guidance, what changed is the operational detail. Who to screen, what to retest and when, which stiffness value triggers referral, and where the approved drugs fit. Pathways that name numbers and doors are harder to skip than pathways that gesture at vigilance.
The age rule deserves one more plain-language pass, because it changes real results. A 68-year-old with a FIB-4 of 1.6 sits in a different position than a 45-year-old with the same score: the pathway treats the older threshold, below 2.0, as the low-risk line for that age group, precisely because platelets and enzyme levels shift with age in ways that inflate the formula. The same score can mean check-in-two-years for one reader and get-scanned for another.
Cost and access belong in the practical paragraph too. FIB-4 is essentially free, built from blood work most patients with metabolic risk factors already have. Elastography availability varies by region and insurance, which is why the pathway names the enhanced liver fibrosis blood test as the accepted fallback rather than pretending every clinic has a FibroScan in the building. Knowing the fallback exists is worth asking about if a referral stalls.
The closing frame for this site’s audience: FIB-4 decides who gets checked, elastography decides who gets referred, and the daily plate decides who stays low-risk long enough that neither visit is ever needed. All three layers are real, and only the third one is fully in the reader’s hands.
Is a FIB-4 score above 1.3 bad for your liver?
It is a signal to check further, not a diagnosis. The 2026 pathway treats FIB-4 above 1.3 (or above 2.0 for adults 65 and older) as the trigger for a second-tier test, usually a liver stiffness measurement. Many people above 1.3 turn out to have low-risk scarring once stiffness is measured; the number decides who gets checked, not who has disease.
What does an 8 kPa liver stiffness reading mean?
Below 8.0 kPa is considered low risk in the 2026 pathway. At or above 8.0 kPa, the recommendation is hepatology referral and possible confirmatory testing, because stiffness in that range raises the probability of advanced fibrosis that changes management.
Can I calculate FIB-4 myself?
Yes, it uses four routine values: age, AST, ALT, and platelet count. Several calculators compute it from standard blood-work numbers. The 2026 pathway adds a rule people miss: for adults 65 and older, the low-risk cutoff rises to below 2.0, which reduces false alarms in that age group.